Pricing, Reimbursement At Center of China Industry Reform Pleas
This article was originally published in PharmAsia News
Amid widening pessimism, Chinese domestic pharma executives have voiced few signs of relief at an annual "meet the regulators' session in which concerns are aired and candid views shared.
You may also be interested in...
2016 was again another busy year on the commercial front in China, with market changes, new regulations, and ongoing pricing pressures all affecting the pharma sector. Meanwhile, the push for licensing deals, innovation, and international expansion continued apace.
One year after the first cases of a novel coronavirus emerged in Wuhan, a team from the World Health Organization has arrived in the city to investigate its origin. Meanwhile, mixed results are reported for some of the leading Chinese vaccines being developed to fight the pandemic still wreaking global havoc.
China's innovative drug makers step into the spotlight by grabbing green lights for cancer drugs in the country's latest batch of product approvals.